Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells

A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)

Philippe Bourin, Bruce A. Bunnell, Louis Casteilla, Massimo Dominici, Adam J. Katz, Keith L. March, Heinz Redl, J. Peter Rubin, Kotaro Yoshimura, Jeffrey M. Gimble

Research output: Contribution to journalArticle

639 Citations (Scopus)

Abstract

Background aims: Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and International Society for Cellular Therapy, this paper sets out to establish minimal definitions of stromal cells both as uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Methods: Phenotypic and functional criteria for the identification of adipose-derived cells were drawn from the literature. Results: In the SVF, cells are identified phenotypically by the following markers: CD45-CD235a-CD31-CD34+. Added value may be provided by both a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The fibroblastoid colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and osteoblastic differentiation assays serve to complete the cell identification and potency assessment in conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase chain reaction. Conclusions: The goal of this paper is to provide initial guidance for the scientific community working with adipose-derived cells and to facilitate development of international standards based on reproducible parameters.

Original languageEnglish
Pages (from-to)641-648
Number of pages8
JournalCytotherapy
Volume15
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Stromal Cells
Blood Vessels
Adipose Tissue
Mesenchymal Stromal Cells
Stem Cells
Population
Colony-Forming Units Assay
Therapeutics
Regenerative Medicine
Surface Antigens
Reverse Transcription
Bone Marrow
Polymerase Chain Reaction

Keywords

  • adipose tissue
  • adipose-derived stromal/stem cells
  • characterization
  • function
  • phenotype
  • stromal vascular fraction

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells : A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). / Bourin, Philippe; Bunnell, Bruce A.; Casteilla, Louis; Dominici, Massimo; Katz, Adam J.; March, Keith L.; Redl, Heinz; Rubin, J. Peter; Yoshimura, Kotaro; Gimble, Jeffrey M.

In: Cytotherapy, Vol. 15, No. 6, 06.2013, p. 641-648.

Research output: Contribution to journalArticle

Bourin, Philippe ; Bunnell, Bruce A. ; Casteilla, Louis ; Dominici, Massimo ; Katz, Adam J. ; March, Keith L. ; Redl, Heinz ; Rubin, J. Peter ; Yoshimura, Kotaro ; Gimble, Jeffrey M. / Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells : A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). In: Cytotherapy. 2013 ; Vol. 15, No. 6. pp. 641-648.
@article{61bab9e472e2460b939746ffe30b0d94,
title = "Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)",
abstract = "Background aims: Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and International Society for Cellular Therapy, this paper sets out to establish minimal definitions of stromal cells both as uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Methods: Phenotypic and functional criteria for the identification of adipose-derived cells were drawn from the literature. Results: In the SVF, cells are identified phenotypically by the following markers: CD45-CD235a-CD31-CD34+. Added value may be provided by both a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The fibroblastoid colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and osteoblastic differentiation assays serve to complete the cell identification and potency assessment in conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase chain reaction. Conclusions: The goal of this paper is to provide initial guidance for the scientific community working with adipose-derived cells and to facilitate development of international standards based on reproducible parameters.",
keywords = "adipose tissue, adipose-derived stromal/stem cells, characterization, function, phenotype, stromal vascular fraction",
author = "Philippe Bourin and Bunnell, {Bruce A.} and Louis Casteilla and Massimo Dominici and Katz, {Adam J.} and March, {Keith L.} and Heinz Redl and Rubin, {J. Peter} and Kotaro Yoshimura and Gimble, {Jeffrey M.}",
year = "2013",
month = "6",
doi = "10.1016/j.jcyt.2013.02.006",
language = "English",
volume = "15",
pages = "641--648",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells

T2 - A joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT)

AU - Bourin, Philippe

AU - Bunnell, Bruce A.

AU - Casteilla, Louis

AU - Dominici, Massimo

AU - Katz, Adam J.

AU - March, Keith L.

AU - Redl, Heinz

AU - Rubin, J. Peter

AU - Yoshimura, Kotaro

AU - Gimble, Jeffrey M.

PY - 2013/6

Y1 - 2013/6

N2 - Background aims: Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and International Society for Cellular Therapy, this paper sets out to establish minimal definitions of stromal cells both as uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Methods: Phenotypic and functional criteria for the identification of adipose-derived cells were drawn from the literature. Results: In the SVF, cells are identified phenotypically by the following markers: CD45-CD235a-CD31-CD34+. Added value may be provided by both a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The fibroblastoid colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and osteoblastic differentiation assays serve to complete the cell identification and potency assessment in conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase chain reaction. Conclusions: The goal of this paper is to provide initial guidance for the scientific community working with adipose-derived cells and to facilitate development of international standards based on reproducible parameters.

AB - Background aims: Adipose tissue is a rich and very convenient source of cells for regenerative medicine therapeutic approaches. However, a characterization of the population of adipose-derived stromal and stem cells (ASCs) with the greatest therapeutic potential remains unclear. Under the authority of International Federation of Adipose Therapeutics and International Society for Cellular Therapy, this paper sets out to establish minimal definitions of stromal cells both as uncultured stromal vascular fraction (SVF) and as an adherent stromal/stem cells population. Methods: Phenotypic and functional criteria for the identification of adipose-derived cells were drawn from the literature. Results: In the SVF, cells are identified phenotypically by the following markers: CD45-CD235a-CD31-CD34+. Added value may be provided by both a viability marker and the following surface antigens: CD13, CD73, CD90 and CD105. The fibroblastoid colony-forming unit assay permits the evaluation of progenitor frequency in the SVF population. In culture, ASCs retain markers in common with other mesenchymal stromal/stem cells (MSCs), including CD90, CD73, CD105, and CD44 and remain negative for CD45 and CD31. They can be distinguished from bone-marrow-derived MSCs by their positivity for CD36 and negativity for CD106. The CFU-F assay is recommended to calculate population doublings capacity of ASCs. The adipocytic, chondroblastic and osteoblastic differentiation assays serve to complete the cell identification and potency assessment in conjunction with a quantitative evaluation of the differentiation either biochemically or by reverse transcription polymerase chain reaction. Conclusions: The goal of this paper is to provide initial guidance for the scientific community working with adipose-derived cells and to facilitate development of international standards based on reproducible parameters.

KW - adipose tissue

KW - adipose-derived stromal/stem cells

KW - characterization

KW - function

KW - phenotype

KW - stromal vascular fraction

UR - http://www.scopus.com/inward/record.url?scp=84877577935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877577935&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.02.006

DO - 10.1016/j.jcyt.2013.02.006

M3 - Article

VL - 15

SP - 641

EP - 648

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -